Global Companion Diagnostic Tests in Oncology Market 2022 by Company, Regions, Type and Application, Forecast to 2028

  • receipt Report ID : 324228
  • calendar_today Published On: Jan, 2023
  • file_copy Pages: 165
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The Companion Diagnostic Tests in Oncology market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest study, due to COVID-19 pandemic, the global Companion Diagnostic Tests in Oncology market size is estimated to be worth US$ 4012 million in 2021 and is forecast to a readjusted size of USD 7377.3 million by 2028 with a CAGR of 9.1% during review period. Pharmaceutical & Biotechnology Companies accounting for % of the Companion Diagnostic Tests in Oncology global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Protein Detection segment is altered to a % CAGR between 2022 and 2028.

Global key companies of Companion Diagnostic Tests in Oncology include Abbott, Roche, Genomic Health, QIAGEN, and Agilent, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

Companion Diagnostic Tests in Oncology market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Protein Detection

DNA Detection

Market segment by Application, can be divided into

Pharmaceutical & Biotechnology Companies

Medical Device Companies

Research Institutes

Others

Market segment by players, this report covers

Abbott

Roche

Genomic Health

QIAGEN

Agilent

Agendia

BioMerieux

Illumina

Siemens Healthcare

Thermo Fisher

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:

Chapter 1, to describe Companion Diagnostic Tests in Oncology product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Companion Diagnostic Tests in Oncology, with revenue, gross margin and global market share of Companion Diagnostic Tests in Oncology from 2019 to 2022.

Chapter 3, the Companion Diagnostic Tests in Oncology competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Companion Diagnostic Tests in Oncology market forecast, by regions, type and application, with revenue, from 2023 to 2028.

Chapter 11 and 12, to describe Companion Diagnostic Tests in Oncology research findings and conclusion, appendix and data source.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of Companion Diagnostic Tests in Oncology

1.2 Classification of Companion Diagnostic Tests in Oncology by Type

1.2.1 Overview: Global Companion Diagnostic Tests in Oncology Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global Companion Diagnostic Tests in Oncology Revenue Market Share by Type in 2021

1.2.3 Protein Detection

1.2.4 DNA Detection

1.3 Global Companion Diagnostic Tests in Oncology Market by Application

1.3.1 Overview: Global Companion Diagnostic Tests in Oncology Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Pharmaceutical & Biotechnology Companies

1.3.3 Medical Device Companies

1.3.4 Research Institutes

1.3.5 Others

1.4 Global Companion Diagnostic Tests in Oncology Market Size & Forecast

1.5 Global Companion Diagnostic Tests in Oncology Market Size and Forecast by Region

1.5.1 Global Companion Diagnostic Tests in Oncology Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global Companion Diagnostic Tests in Oncology Market Size by Region, (2017-2022)

1.5.3 North America Companion Diagnostic Tests in Oncology Market Size and Prospect (2017-2028)

1.5.4 Europe Companion Diagnostic Tests in Oncology Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific Companion Diagnostic Tests in Oncology Market Size and Prospect (2017-2028)

1.5.6 South America Companion Diagnostic Tests in Oncology Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa Companion Diagnostic Tests in Oncology Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 Companion Diagnostic Tests in Oncology Market Drivers

1.6.2 Companion Diagnostic Tests in Oncology Market Restraints

1.6.3 Companion Diagnostic Tests in Oncology Trends Analysis

2 Company Profiles

2.1 Abbott

2.1.1 Abbott Details

2.1.2 Abbott Major Business

2.1.3 Abbott Companion Diagnostic Tests in Oncology Product and Solutions

2.1.4 Abbott Companion Diagnostic Tests in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 Abbott Recent Developments and Future Plans

2.2 Roche

2.2.1 Roche Details

2.2.2 Roche Major Business

2.2.3 Roche Companion Diagnostic Tests in Oncology Product and Solutions

2.2.4 Roche Companion Diagnostic Tests in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 Roche Recent Developments and Future Plans

2.3 Genomic Health

2.3.1 Genomic Health Details

2.3.2 Genomic Health Major Business

2.3.3 Genomic Health Companion Diagnostic Tests in Oncology Product and Solutions

2.3.4 Genomic Health Companion Diagnostic Tests in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 Genomic Health Recent Developments and Future Plans

2.4 QIAGEN

2.4.1 QIAGEN Details

2.4.2 QIAGEN Major Business

2.4.3 QIAGEN Companion Diagnostic Tests in Oncology Product and Solutions

2.4.4 QIAGEN Companion Diagnostic Tests in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 QIAGEN Recent Developments and Future Plans

2.5 Agilent

2.5.1 Agilent Details

2.5.2 Agilent Major Business

2.5.3 Agilent Companion Diagnostic Tests in Oncology Product and Solutions

2.5.4 Agilent Companion Diagnostic Tests in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 Agilent Recent Developments and Future Plans

2.6 Agendia

2.6.1 Agendia Details

2.6.2 Agendia Major Business

2.6.3 Agendia Companion Diagnostic Tests in Oncology Product and Solutions

2.6.4 Agendia Companion Diagnostic Tests in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6.5 Agendia Recent Developments and Future Plans

2.7 BioMerieux

2.7.1 BioMerieux Details

2.7.2 BioMerieux Major Business

2.7.3 BioMerieux Companion Diagnostic Tests in Oncology Product and Solutions

2.7.4 BioMerieux Companion Diagnostic Tests in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7.5 BioMerieux Recent Developments and Future Plans

2.8 Illumina

2.8.1 Illumina Details

2.8.2 Illumina Major Business

2.8.3 Illumina Companion Diagnostic Tests in Oncology Product and Solutions

2.8.4 Illumina Companion Diagnostic Tests in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.8.5 Illumina Recent Developments and Future Plans

2.9 Siemens Healthcare

2.9.1 Siemens Healthcare Details

2.9.2 Siemens Healthcare Major Business

2.9.3 Siemens Healthcare Companion Diagnostic Tests in Oncology Product and Solutions

2.9.4 Siemens Healthcare Companion Diagnostic Tests in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9.5 Siemens Healthcare Recent Developments and Future Plans

2.10 Thermo Fisher

2.10.1 Thermo Fisher Details

2.10.2 Thermo Fisher Major Business

2.10.3 Thermo Fisher Companion Diagnostic Tests in Oncology Product and Solutions

2.10.4 Thermo Fisher Companion Diagnostic Tests in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10.5 Thermo Fisher Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Companion Diagnostic Tests in Oncology Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 Companion Diagnostic Tests in Oncology Players Market Share in 2021

3.2.2 Top 10 Companion Diagnostic Tests in Oncology Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 Companion Diagnostic Tests in Oncology Players Head Office, Products and Services Provided

3.4 Companion Diagnostic Tests in Oncology Mergers & Acquisitions

3.5 Companion Diagnostic Tests in Oncology New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Companion Diagnostic Tests in Oncology Revenue and Market Share by Type (2017-2022)

4.2 Global Companion Diagnostic Tests in Oncology Market Forecast by Type (2023-2028)

5 Market Size Segment by Application

5.1 Global Companion Diagnostic Tests in Oncology Revenue Market Share by Application (2017-2022)

5.2 Global Companion Diagnostic Tests in Oncology Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application

6.1 North America Companion Diagnostic Tests in Oncology Revenue by Type (2017-2028)

6.2 North America Companion Diagnostic Tests in Oncology Revenue by Application (2017-2028)

6.3 North America Companion Diagnostic Tests in Oncology Market Size by Country

6.3.1 North America Companion Diagnostic Tests in Oncology Revenue by Country (2017-2028)

6.3.2 United States Companion Diagnostic Tests in Oncology Market Size and Forecast (2017-2028)

6.3.3 Canada Companion Diagnostic Tests in Oncology Market Size and Forecast (2017-2028)

6.3.4 Mexico Companion Diagnostic Tests in Oncology Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application

7.1 Europe Companion Diagnostic Tests in Oncology Revenue by Type (2017-2028)

7.2 Europe Companion Diagnostic Tests in Oncology Revenue by Application (2017-2028)

7.3 Europe Companion Diagnostic Tests in Oncology Market Size by Country

7.3.1 Europe Companion Diagnostic Tests in Oncology Revenue by Country (2017-2028)

7.3.2 Germany Companion Diagnostic Tests in Oncology Market Size and Forecast (2017-2028)

7.3.3 France Companion Diagnostic Tests in Oncology Market Size and Forecast (2017-2028)

7.3.4 United Kingdom Companion Diagnostic Tests in Oncology Market Size and Forecast (2017-2028)

7.3.5 Russia Companion Diagnostic Tests in Oncology Market Size and Forecast (2017-2028)

7.3.6 Italy Companion Diagnostic Tests in Oncology Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Companion Diagnostic Tests in Oncology Revenue by Type (2017-2028)

8.2 Asia-Pacific Companion Diagnostic Tests in Oncology Revenue by Application (2017-2028)

8.3 Asia-Pacific Companion Diagnostic Tests in Oncology Market Size by Region

8.3.1 Asia-Pacific Companion Diagnostic Tests in Oncology Revenue by Region (2017-2028)

8.3.2 China Companion Diagnostic Tests in Oncology Market Size and Forecast (2017-2028)

8.3.3 Japan Companion Diagnostic Tests in Oncology Market Size and Forecast (2017-2028)

8.3.4 South Korea Companion Diagnostic Tests in Oncology Market Size and Forecast (2017-2028)

8.3.5 India Companion Diagnostic Tests in Oncology Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia Companion Diagnostic Tests in Oncology Market Size and Forecast (2017-2028)

8.3.7 Australia Companion Diagnostic Tests in Oncology Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application

9.1 South America Companion Diagnostic Tests in Oncology Revenue by Type (2017-2028)

9.2 South America Companion Diagnostic Tests in Oncology Revenue by Application (2017-2028)

9.3 South America Companion Diagnostic Tests in Oncology Market Size by Country

9.3.1 South America Companion Diagnostic Tests in Oncology Revenue by Country (2017-2028)

9.3.2 Brazil Companion Diagnostic Tests in Oncology Market Size and Forecast (2017-2028)

9.3.3 Argentina Companion Diagnostic Tests in Oncology Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Companion Diagnostic Tests in Oncology Revenue by Type (2017-2028)

10.2 Middle East & Africa Companion Diagnostic Tests in Oncology Revenue by Application (2017-2028)

10.3 Middle East & Africa Companion Diagnostic Tests in Oncology Market Size by Country

10.3.1 Middle East & Africa Companion Diagnostic Tests in Oncology Revenue by Country (2017-2028)

10.3.2 Turkey Companion Diagnostic Tests in Oncology Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia Companion Diagnostic Tests in Oncology Market Size and Forecast (2017-2028)

10.3.4 UAE Companion Diagnostic Tests in Oncology Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Companion Diagnostic Tests in Oncology Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global Companion Diagnostic Tests in Oncology Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market Companion Diagnostic Tests in Oncology Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global Companion Diagnostic Tests in Oncology Revenue (USD Million) by Region (2017-2022)

Table 5. Global Companion Diagnostic Tests in Oncology Revenue Market Share by Region (2023-2028)

Table 6. Abbott Corporate Information, Head Office, and Major Competitors

Table 7. Abbott Major Business

Table 8. Abbott Companion Diagnostic Tests in Oncology Product and Solutions

Table 9. Abbott Companion Diagnostic Tests in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. Roche Corporate Information, Head Office, and Major Competitors

Table 11. Roche Major Business

Table 12. Roche Companion Diagnostic Tests in Oncology Product and Solutions

Table 13. Roche Companion Diagnostic Tests in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. Genomic Health Corporate Information, Head Office, and Major Competitors

Table 15. Genomic Health Major Business

Table 16. Genomic Health Companion Diagnostic Tests in Oncology Product and Solutions

Table 17. Genomic Health Companion Diagnostic Tests in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. QIAGEN Corporate Information, Head Office, and Major Competitors

Table 19. QIAGEN Major Business

Table 20. QIAGEN Companion Diagnostic Tests in Oncology Product and Solutions

Table 21. QIAGEN Companion Diagnostic Tests in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. Agilent Corporate Information, Head Office, and Major Competitors

Table 23. Agilent Major Business

Table 24. Agilent Companion Diagnostic Tests in Oncology Product and Solutions

Table 25. Agilent Companion Diagnostic Tests in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. Agendia Corporate Information, Head Office, and Major Competitors

Table 27. Agendia Major Business

Table 28. Agendia Companion Diagnostic Tests in Oncology Product and Solutions

Table 29. Agendia Companion Diagnostic Tests in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. BioMerieux Corporate Information, Head Office, and Major Competitors

Table 31. BioMerieux Major Business

Table 32. BioMerieux Companion Diagnostic Tests in Oncology Product and Solutions

Table 33. BioMerieux Companion Diagnostic Tests in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 34. Illumina Corporate Information, Head Office, and Major Competitors

Table 35. Illumina Major Business

Table 36. Illumina Companion Diagnostic Tests in Oncology Product and Solutions

Table 37. Illumina Companion Diagnostic Tests in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 38. Siemens Healthcare Corporate Information, Head Office, and Major Competitors

Table 39. Siemens Healthcare Major Business

Table 40. Siemens Healthcare Companion Diagnostic Tests in Oncology Product and Solutions

Table 41. Siemens Healthcare Companion Diagnostic Tests in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 42. Thermo Fisher Corporate Information, Head Office, and Major Competitors

Table 43. Thermo Fisher Major Business

Table 44. Thermo Fisher Companion Diagnostic Tests in Oncology Product and Solutions

Table 45. Thermo Fisher Companion Diagnostic Tests in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 46. Global Companion Diagnostic Tests in Oncology Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 47. Global Companion Diagnostic Tests in Oncology Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 48. Breakdown of Companion Diagnostic Tests in Oncology by Company Type (Tier 1, Tier 2 and Tier 3)

Table 49. Companion Diagnostic Tests in Oncology Players Head Office, Products and Services Provided

Table 50. Companion Diagnostic Tests in Oncology Mergers & Acquisitions in the Past Five Years

Table 51. Companion Diagnostic Tests in Oncology New Entrants and Expansion Plans

Table 52. Global Companion Diagnostic Tests in Oncology Revenue (USD Million) by Type (2017-2022)

Table 53. Global Companion Diagnostic Tests in Oncology Revenue Share by Type (2017-2022)

Table 54. Global Companion Diagnostic Tests in Oncology Revenue Forecast by Type (2023-2028)

Table 55. Global Companion Diagnostic Tests in Oncology Revenue by Application (2017-2022)

Table 56. Global Companion Diagnostic Tests in Oncology Revenue Forecast by Application (2023-2028)

Table 57. North America Companion Diagnostic Tests in Oncology Revenue by Type (2017-2022) & (USD Million)

Table 58. North America Companion Diagnostic Tests in Oncology Revenue by Type (2023-2028) & (USD Million)

Table 59. North America Companion Diagnostic Tests in Oncology Revenue by Application (2017-2022) & (USD Million)

Table 60. North America Companion Diagnostic Tests in Oncology Revenue by Application (2023-2028) & (USD Million)

Table 61. North America Companion Diagnostic Tests in Oncology Revenue by Country (2017-2022) & (USD Million)

Table 62. North America Companion Diagnostic Tests in Oncology Revenue by Country (2023-2028) & (USD Million)

Table 63. Europe Companion Diagnostic Tests in Oncology Revenue by Type (2017-2022) & (USD Million)

Table 64. Europe Companion Diagnostic Tests in Oncology Revenue by Type (2023-2028) & (USD Million)

Table 65. Europe Companion Diagnostic Tests in Oncology Revenue by Application (2017-2022) & (USD Million)

Table 66. Europe Companion Diagnostic Tests in Oncology Revenue by Application (2023-2028) & (USD Million)

Table 67. Europe Companion Diagnostic Tests in Oncology Revenue by Country (2017-2022) & (USD Million)

Table 68. Europe Companion Diagnostic Tests in Oncology Revenue by Country (2023-2028) & (USD Million)

Table 69. Asia-Pacific Companion Diagnostic Tests in Oncology Revenue by Type (2017-2022) & (USD Million)

Table 70. Asia-Pacific Companion Diagnostic Tests in Oncology Revenue by Type (2023-2028) & (USD Million)

Table 71. Asia-Pacific Companion Diagnostic Tests in Oncology Revenue by Application (2017-2022) & (USD Million)

Table 72. Asia-Pacific Companion Diagnostic Tests in Oncology Revenue by Application (2023-2028) & (USD Million)

Table 73. Asia-Pacific Companion Diagnostic Tests in Oncology Revenue by Region (2017-2022) & (USD Million)

Table 74. Asia-Pacific Companion Diagnostic Tests in Oncology Revenue by Region (2023-2028) & (USD Million)

Table 75. South America Companion Diagnostic Tests in Oncology Revenue by Type (2017-2022) & (USD Million)

Table 76. South America Companion Diagnostic Tests in Oncology Revenue by Type (2023-2028) & (USD Million)

Table 77. South America Companion Diagnostic Tests in Oncology Revenue by Application (2017-2022) & (USD Million)

Table 78. South America Companion Diagnostic Tests in Oncology Revenue by Application (2023-2028) & (USD Million)

Table 79. South America Companion Diagnostic Tests in Oncology Revenue by Country (2017-2022) & (USD Million)

Table 80. South America Companion Diagnostic Tests in Oncology Revenue by Country (2023-2028) & (USD Million)

Table 81. Middle East & Africa Companion Diagnostic Tests in Oncology Revenue by Type (2017-2022) & (USD Million)

Table 82. Middle East & Africa Companion Diagnostic Tests in Oncology Revenue by Type (2023-2028) & (USD Million)

Table 83. Middle East & Africa Companion Diagnostic Tests in Oncology Revenue by Application (2017-2022) & (USD Million)

Table 84. Middle East & Africa Companion Diagnostic Tests in Oncology Revenue by Application (2023-2028) & (USD Million)

Table 85. Middle East & Africa Companion Diagnostic Tests in Oncology Revenue by Country (2017-2022) & (USD Million)

Table 86. Middle East & Africa Companion Diagnostic Tests in Oncology Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. Companion Diagnostic Tests in Oncology Picture

Figure 2. Global Companion Diagnostic Tests in Oncology Revenue Market Share by Type in 2021

Figure 3. Protein Detection

Figure 4. DNA Detection

Figure 5. Companion Diagnostic Tests in Oncology Revenue Market Share by Application in 2021

Figure 6. Pharmaceutical & Biotechnology Companies Picture

Figure 7. Medical Device Companies Picture

Figure 8. Research Institutes Picture

Figure 9. Others Picture

Figure 10. Global Companion Diagnostic Tests in Oncology Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 11. Global Companion Diagnostic Tests in Oncology Revenue and Forecast (2017-2028) & (USD Million)

Figure 12. Global Companion Diagnostic Tests in Oncology Revenue Market Share by Region (2017-2028)

Figure 13. Global Companion Diagnostic Tests in Oncology Revenue Market Share by Region in 2021

Figure 14. North America Companion Diagnostic Tests in Oncology Revenue (USD Million) and Growth Rate (2017-2028)

Figure 15. Europe Companion Diagnostic Tests in Oncology Revenue (USD Million) and Growth Rate (2017-2028)

Figure 16. Asia-Pacific Companion Diagnostic Tests in Oncology Revenue (USD Million) and Growth Rate (2017-2028)

Figure 17. South America Companion Diagnostic Tests in Oncology Revenue (USD Million) and Growth Rate (2017-2028)

Figure 18. Middle East and Africa Companion Diagnostic Tests in Oncology Revenue (USD Million) and Growth Rate (2017-2028)

Figure 19. Companion Diagnostic Tests in Oncology Market Drivers

Figure 20. Companion Diagnostic Tests in Oncology Market Restraints

Figure 21. Companion Diagnostic Tests in Oncology Market Trends

Figure 22. Abbott Recent Developments and Future Plans

Figure 23. Roche Recent Developments and Future Plans

Figure 24. Genomic Health Recent Developments and Future Plans

Figure 25. QIAGEN Recent Developments and Future Plans

Figure 26. Agilent Recent Developments and Future Plans

Figure 27. Agendia Recent Developments and Future Plans

Figure 28. BioMerieux Recent Developments and Future Plans

Figure 29. Illumina Recent Developments and Future Plans

Figure 30. Siemens Healthcare Recent Developments and Future Plans

Figure 31. Thermo Fisher Recent Developments and Future Plans

Figure 32. Global Companion Diagnostic Tests in Oncology Revenue Share by Players in 2021

Figure 33. Companion Diagnostic Tests in Oncology Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 34. Global Top 3 Players Companion Diagnostic Tests in Oncology Revenue Market Share in 2021

Figure 35. Global Top 10 Players Companion Diagnostic Tests in Oncology Revenue Market Share in 2021

Figure 36. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 37. Global Companion Diagnostic Tests in Oncology Revenue Share by Type in 2021

Figure 38. Global Companion Diagnostic Tests in Oncology Market Share Forecast by Type (2023-2028)

Figure 39. Global Companion Diagnostic Tests in Oncology Revenue Share by Application in 2021

Figure 40. Global Companion Diagnostic Tests in Oncology Market Share Forecast by Application (2023-2028)

Figure 41. North America Companion Diagnostic Tests in Oncology Sales Market Share by Type (2017-2028)

Figure 42. North America Companion Diagnostic Tests in Oncology Sales Market Share by Application (2017-2028)

Figure 43. North America Companion Diagnostic Tests in Oncology Revenue Market Share by Country (2017-2028)

Figure 44. United States Companion Diagnostic Tests in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 45. Canada Companion Diagnostic Tests in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 46. Mexico Companion Diagnostic Tests in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 47. Europe Companion Diagnostic Tests in Oncology Sales Market Share by Type (2017-2028)

Figure 48. Europe Companion Diagnostic Tests in Oncology Sales Market Share by Application (2017-2028)

Figure 49. Europe Companion Diagnostic Tests in Oncology Revenue Market Share by Country (2017-2028)

Figure 50. Germany Companion Diagnostic Tests in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 51. France Companion Diagnostic Tests in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 52. United Kingdom Companion Diagnostic Tests in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 53. Russia Companion Diagnostic Tests in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 54. Italy Companion Diagnostic Tests in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 55. Asia-Pacific Companion Diagnostic Tests in Oncology Sales Market Share by Type (2017-2028)

Figure 56. Asia-Pacific Companion Diagnostic Tests in Oncology Sales Market Share by Application (2017-2028)

Figure 57. Asia-Pacific Companion Diagnostic Tests in Oncology Revenue Market Share by Region (2017-2028)

Figure 58. China Companion Diagnostic Tests in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 59. Japan Companion Diagnostic Tests in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 60. South Korea Companion Diagnostic Tests in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 61. India Companion Diagnostic Tests in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 62. Southeast Asia Companion Diagnostic Tests in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 63. Australia Companion Diagnostic Tests in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 64. South America Companion Diagnostic Tests in Oncology Sales Market Share by Type (2017-2028)

Figure 65. South America Companion Diagnostic Tests in Oncology Sales Market Share by Application (2017-2028)

Figure 66. South America Companion Diagnostic Tests in Oncology Revenue Market Share by Country (2017-2028)

Figure 67. Brazil Companion Diagnostic Tests in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 68. Argentina Companion Diagnostic Tests in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 69. Middle East and Africa Companion Diagnostic Tests in Oncology Sales Market Share by Type (2017-2028)

Figure 70. Middle East and Africa Companion Diagnostic Tests in Oncology Sales Market Share by Application (2017-2028)

Figure 71. Middle East and Africa Companion Diagnostic Tests in Oncology Revenue Market Share by Country (2017-2028)

Figure 72. Turkey Companion Diagnostic Tests in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 73. Saudi Arabia Companion Diagnostic Tests in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 74. UAE Companion Diagnostic Tests in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 75. Methodology

Figure 76. Research Process and Data Source

shopping_cart License Type

Buy Now

email Quick Contact

tag_faces Our Clients

help Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketsandresearch.biz